Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Imatinib Mesylate Reduces Production Of Extracellular Matrix And Prevents Development Of Experimental Dermal Fibrosis


  • Please log in to reply
No replies to this topic

#1 Guest_Sherrill_*

Guest_Sherrill_*
  • Guests

Posted 08 June 2007 - 08:10 PM

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Considering its favorable pharmacokinetics and clinical experience with its use in other diseases, imatinib mesylate is a promising candidate for the treatment of fibrotic diseases such as SSc. PubMed. Arthritis rheumatologist. 2007 Jan;56(1):9-12. (Also see: Skin Fibrosis and Scleroderma Treatments)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information. http://www.sclero.org/news/a-to-z.html